CHAIN Wins Grants to Expand Platform
CHAIN has been awarded two grants to support its therapeutic delivery platform from Innovate...
read more
CHAIN Biotechnology Ltd was founded by Dr Edward Green in 2014 to develop new Clostridium-based microbial technology for high value healthcare products. CHAIN produces novel live biotherapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD).
At the heart of CHAIN’s unique therapeutic platform is a suite of underpinning technologies including a Clostridia culture collection, a proprietary set of plasmid vectors, synthetic biology tools for advanced metabolic engineering, and an advanced in-vivo delivery mechanism using Clostridium.